MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- AUROBINDO PHARMA (pharmaceuticals)
- Latest 8 Quarter Result
AUROBINDO PHARMA Quarterly Results (AUBD)
Here are the latest quarterly results of AUROBINDO PHARMA. For more details, see the AUROBINDO PHARMA financial fact sheet and AUROBINDO PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
AUROBINDO PHARMA Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
3
Mar-21* |
3
Jun-21* |
3
Sep-21* |
3
Dec-21* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 61,584 | 59,248 | 64,834 | 63,649 | 60,015 | 57,020 | 59,419 | 60,022 | |
| Other income | Rs m | 326 | 1,156 | 538 | 1,334 | 781 | 1,099 | 966 | 650 | |
| Turnover | Rs m | 61,910 | 60,404 | 65,372 | 64,983 | 60,796 | 58,119 | 60,385 | 60,672 | |
| Expenses | Rs m | 48,422 | 46,674 | 50,506 | 49,963 | 47,268 | 44,926 | 47,552 | 49,860 | |
| Gross profit | Rs m | 13,285 | 12,574 | 14,328 | 41,825 | 12,754 | 12,094 | 11,867 | 10,511 | |
| Depreciation | Rs m | 2,324 | 2,555 | 2,573 | 2,765 | 2,660 | 2,797 | 2,942 | 2,991 | |
| Interest | Rs m | 318 | 211 | 157 | 195 | 182 | 129 | 104 | 161 | |
| Profit before tax | Rs m | 10,968 | 10,964 | 12,135 | 40,199 | 10,692 | 10,267 | 9,787 | 8,009 | |
| Tax | Rs m | 2,144 | 3,012 | 3,857 | 10,575 | 2,597 | 2,477 | 2,709 | 1,895 | |
| Profit after tax | Rs m | 8,825 | 7,952 | 8,278 | 29,624 | 8,096 | 7,790 | 7,078 | 6,114 | |
| Gross profit margin | % | 21.6 | 21.2 | 22.1 | 65.7 | 21.3 | 21.2 | 20.0 | 17.5 | |
| Effective tax rate | % | 19.5 | 27.5 | 31.8 | 26.3 | 24.3 | 24.1 | 27.7 | 23.7 | |
| Net profit margin | % | 14.3 | 13.4 | 12.8 | 46.5 | 13.5 | 13.7 | 11.9 | 10.2 | |
| Diluted EPS | Rs | 15.1 | 13.6 | 14.1 | 50.6 | 13.8 | 13.3 | 12.1 | 10.4 | |
| Diluted EPS (TTM) | Rs | 48.8 | 51.6 | 54.8 | 93.3 | 92.1 | 91.8 | 89.7 | 49.6 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Today's Market
Sensex Rallies 632 Points, Nifty Ends Above 16,350; Banking & IT Stocks Witness Buying(Closing)
Indian share markets rose today as easing bets about aggressive interest rate hikes by central banks lifted sentiment.
Views on news
Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary (Views On News)
Jul 2, 2021Here's why the company sold its business unit to Eugia Pharma Specialities.
Aurobindo Pharma's Stock Falls After Profits Decline 7% (Views On News)
Jun 1, 2021Aurobindo Pharma shares fell nearly 4% after quarterly earnings disappoint.
Why Divi's Lab Share Price is Falling (Views On News)
May 24, 2022Here's why Divi's Lab's stock fell over 10% in two days.
Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)
May 23, 2022For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)
May 19, 2022During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
More Views on NewsMost Popular
2022's Best Performing Penny Stocks So Far... (Views On News)
Mar 2, 2022We are just two months into 2022 and several penny stocks that we track have already surged 5x.
5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022 (Views On News)
Mar 16, 2022Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
Penny Stocks to Buy and Hold Beyond 2022 (Views On News)
Apr 6, 2022A step-by-step method to pick the best penny stocks for the long term.
6 Penny Stocks that Could Be Hidden Bluechips. Take a Look... (Views On News)
Apr 13, 2022These penny stocks can become future multibaggers. Watch out for them.
Adani Power vs Tata Power: Which Power Stock is Better? (Views On News)
Feb 28, 2022Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2022
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: How to Profit from Sensex 100,000
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
AUROBINDO PHARMA SHARE PRICE
May 27, 2022 (Close)
TRACK AUROBINDO PHARMA
- Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AUROBINDO PHARMA
AUROBINDO PHARMA - ACTAVIS COMPARISON
COMPARE AUROBINDO PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks in 2022
FOLLOW
APP
EQUITYMASTER SUPPORTS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.